Rutika Mehta, GI Medical Oncologist and Associate Professor at Weill Cornell Medicine, shared a post on X:
“If we lived in a parallel universe, would we offer IO to our next patient with CLDN18.2 and PD-L1 positive GEA?
Impressive PFS and OS in this single arm cohort. ≥Gr3 nausea 0%- says that experience matters to reduce toxicities.
Liked that oxaliplatin dropped after C5.”
You can also read: Phase II ILUSTRO Trial at ASCO GI 2026: First line Zolbetuximab plus mFOLFOX6 and Nivolumab in CLDN18.2-Positive Gastric/GEJ Adenocarcinoma
